Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS

This article was originally published in The Pink Sheet Daily

Executive Summary

The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.
Advertisement

Related Content

When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Alexion’s Soliris REMS Working Well But Might Benefit From Small Changes
The Downside Of REMS: An Over-Taxed Health Care System – FDA’s Jenkins
FDA Gives Firms With RiskMAP Drugs 6 Months To Submit Strategy Proposals
FDA Gives Firms With RiskMAP Drugs 6 Months To Submit Strategy Proposals

Topics

Advertisement
UsernamePublicRestriction

Register

PS070920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel